UEA School of Biological Sciences

Cancer Research Institute Awards Ananda Goldrath, Ph.D., with the 2023 Frederick W. Alt Award

Retrieved on: 
Monday, October 30, 2023
Tata, Survival, CRI, Harvard Medical School, Leukemia, Allen Institute, Tissue-resident memory T cell, Health, Immunological Genome Project, University of California, San Diego, Cancer Research Institute, UEA School of Biological Sciences, The Pew Charitable Trusts, UCSD, Research, Creativity, Tissue, Fellow, School, Immune system, American Academy, Science, Malignancy, Cancer research, Gene, Biology, National academy, Infection, Vaccine, Management, Immunology

SEATTLE, Oct. 30, 2023 /PRNewswire/ -- The Cancer Research Institute (CRI) has awarded Ananda Goldrath, Ph.D., Executive Vice President and Director of the Allen Institute for Immunology, the 2023 Frederick W. Alt Award. This award is given to former Cancer Research Institute postdoctoral fellows who have achieved outstanding success in academia or industry for innovative research that has advanced knowledge and understanding in the field of immunology.

Key Points: 
  • SEATTLE, Oct. 30, 2023 /PRNewswire/ -- The Cancer Research Institute (CRI) has awarded Ananda Goldrath , Ph.D., Executive Vice President and Director of the Allen Institute for Immunology, the 2023 Frederick W. Alt Award.
  • This award is given to former Cancer Research Institute postdoctoral fellows who have achieved outstanding success in academia or industry for innovative research that has advanced knowledge and understanding in the field of immunology.
  • "The Cancer Research Institute has been supporting the training of young scientists and nurturing careers for decades.
  • Dr. Goldrath will receive the award at the 2023 CRI Annual Awards Dinner on Monday, November 6, in New York City.

GPCR Therapeutics Announces Publication in Nature Scientific Reports on Novel Anticancer Therapy

Retrieved on: 
Wednesday, March 15, 2023
Progression-free survival, G protein-coupled receptor, Drug discovery, Drug development, Therapy, Breast cancer, School, Seoul National University, UEA School of Biological Sciences, H1, Professor, Observation, Calcium signaling, CXC, Patient, Research, Gq alpha subunit, GPCR, Biology, Scientific Reports, HRH1, ADRB2, IRIC, CXCR4, Pharmaceutical industry, Propranolol, Cancer

The simultaneous expression of both receptors leads to the formation of CXCR4-HRH1 heteromer, and this complex demonstrates enhanced signalling and migration capabilities.

Key Points: 
  • The simultaneous expression of both receptors leads to the formation of CXCR4-HRH1 heteromer, and this complex demonstrates enhanced signalling and migration capabilities.
  • These findings suggest the interaction of CXCR4 and HRH1 may play an important role in cancer progression, thus serving as a potential therapeutic target for anticancer therapy.
  • This publication is significant as it represents the first case for our co-targeting drug development strategy to be peer-reviewed and validated in academia.
  • (1) Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration: